Quantcast
Home > Quotes > PRAH

PRA Health Sciences, Inc. Common Stock (PRAH) Quote & Summary Data

PRAH 
$99.32
*  
1.36
1.39%
Get PRAH Alerts
*Delayed - data as of Jul. 18, 2019  -  Find a broker to begin trading PRAH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PRAH After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 99.32 / $ 103
1 Year Target
115
Today's High / Low
$ 99.40 / $ 97.525
Share Volume
619,961
50 Day Avg. Daily Volume
583,531
Previous Close
$ 97.96
52 Week High / Low
$ 121.98 / $ 82.12
Market Cap
6,521,600,692
P/E Ratio
41.56
Forward P/E (1y)
21.20
Earnings Per Share (EPS)
$ 2.39
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.82

Intraday Chart

Shares Traded

Share Volume:
619,961
50 Day Avg. Daily Volume:
583,531

P/E Ratio

P/E Ratio:
41.56
Forward P/E (1y):
21.20
Earnings Per Share (EPS):
$ 2.39

Trading Range

The current last sale of $99.32 is 20.94% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 99.40 $ 121.98
 Low: $ 97.525 $ 82.12

ETFs with PRAH as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.16% Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) +1.15 (2.59%)
1.77% Invesco S&P Midcap 400 Pure Growth ETF (RFG) -7.14 (-4.62%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are one of the world's leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. We believe we are one of a select group of CROs with the expertise and capability to conduct clinical trials across major therapeutic areas on a global basis. Our therapeutic expertise includes areas that are among the largest in pharmaceutical development, and we focus in particular on oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic and infectious diseases. We believe that we further differentiate ourselves from our competitors through our investments in medical informatics and clinical technologies designed to enhance efficiencies, improve study predictability and provide better transparency for our clients throughout their clinical development processes.  ... More ...  



Risk Grade

Where does PRAH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 97.78
Open Date:
Jul. 18, 2019
Close Price:
$ 99.32
Close Date:
Jul. 18, 2019


Consensus Recommendation

Analyst Info